ALPS Medical Breakthroughs ETF

SBIO

Market cap $156M

Sabio Holdings Inc. (SBIO:CA) Q1 2026 Earnings Call Transcript

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Sabio Holdings Inc. (SBIO:CA) Q4 2025 Earnings Call Transcript

The leading articles for last week ran the gamut in terms of topics, but suggest investors are still worried about inflation and remain interested in biotech, nuclear energy, and derivatives strategies. Todd Shriber's article highlighting the recent outsized performance of ALPS's SBIO claimed the top spot.

ALPS Medical Breakthroughs ETF (SBIO) targets late-stage clinical biotech firms poised for FDA approval or acquisition, offering high-risk, high-reward exposure. SBIO surged 91% over the past year, outperforming the S&P 500, driven by sector reflation and successful late-stage catalysts among holdings. The ETF's disciplined screen ensures holdings have sufficient cash, focus on Phase II/III assets, and diversification across oncology and rare diseases.

Broader healthcare ETFs aren't doing much to appease investors this year, but biotech funds are warding off that weakness. Just look at the ALPS Medical Breakthroughs ETF (SBIO).

While some investment themes have struggled to maintain their trajectory, the space economy has proven it has the fundamental fuel to reach escape velocity. This momentum is being met with a strategic modernization of the underlying infrastructure for UFO.

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

A surge in biotech M&A activity drove sharp gains across holdings in the ALPS Medical Breakthroughs ETF (SBIO) during March, with two of the fund's holdings becoming acquisition targets in deals worth a combined $8.1 billion. SBIO gained 8.4% over the past month and rose 9.4% over the past three months.

Iran war reshaped Q1 markets: energy, shipping & lithium ETFs surged while tech and airlines lagged as inflation fears and oil shocks rattled sentiment.